¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"nested case control study"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • longitudinal study
    ÃßÀû¿¬±¸
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • neurophysiological study
    ½Å°æ»ý¸®ÇÐÀû°Ë»ç
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ¿¬±¸
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀÓ»óÀü½ÃÇè, ÀüÀӻ󿬱¸
  • pressure flow study
    ¾Ð·Â¿ä·ù°Ë»ç
  • prospective cohort study
    ÀüÇâÄÚȣƮ¿¬±¸
  • prospective study
    ÀüÇ⿬±¸, °èȹ¿¬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸
  • study
    1. ¿¬±¸, Á¶»ç 2. °Ë»ç, °Ë»ö
  • study design
    ¿¬±¸¼³°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • family study
    °¡Á·Á¶»ç
  • feasibility study
    °¡´É¼º¿¬±¸
  • first pass study
    ÀÏÂ÷Åë°ú°Ë»ç
  • follow-up study
    ÃßÀûÁ¶»ç
  • intervening study
    °³ÀÔ¿¬±¸
  • longitudinal study
    ÃßÀû¿¬±¸
  • microbiologic study
    ¹Ì»ý¹°Çа˻ç
  • migrant study
    ÀÌÁֹבּ¸
  • mixing study
    È¥ÇÕ°Ë»ç
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • neurophysiological study
    ½Å°æ»ý¸®ÇÐÀû°Ë»ç
  • nonconcurrent study
    ºñµ¿½ÃÀû¿¬±¸
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ½ÇÇè
  • population study
    Àα¸Á¶»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • injury control
    »óÇØ°ü¸®(Ë×Ì´Ë´Ëö).
  • predictive value of control signal
    Á¦¾î<´ëÁ¶>½ÅÈ£ÀÇ ¿¹ÃøÄ¡
  • pulse control unit
    ¸Æ¹Ú Á¶Àý ´ÜÀ§
  • quality control
    Á¤µµ°ü¸®
  • quality control
    ǰÁú°ü¸®(̰̤˴Ëö).
  • quality control
    È­Áú °ü¸®, ǰÁú°ü¸®
  • quality control program
    Á¤µµ°ü¸®°èȹ
  • quality control, QC
    ǰÁú°ü¸®, Á¤µµº¸Áõ, Á¤µµ°ü¸®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cohort study
    ÄÚ¿ÀÆ®¿¬±¸(ÊÙËçË´), Æø·ÎºñÆø·Î¿¬±¸.
  • controlled clinical study
    (Ãß°èÇÐÀû) °ü¸®È­(Ì§Ë­Ì°ËøË´ËöÌ´)(ÀÓ»ó)½ÃÇè( ËöË×ËàÌ´).
  • double-blind study
    ÀÌÁ߸ͰË.
  • family study
    °¡Á·Á¶»ç(¿¬±¸)
  • first pass study
    ÀÏÂ÷Åë°ú°Ë»ç.
  • follow-up study
    ÃßÀûÁ¶»ç
  • microbiologic study
    ¹Ì»ý¹°ÇÐÀû °Ë»ç
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇÐ<ÀÚ>°Ë»ç
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • pilot study
    ¿¹ºñ½ÇÇè.
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀüÀÓ»ó½ÃÇè(îñìúßÉãËúÐ).
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • prospective study
    °èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AC abdominal circumference; abdominal compression; absorption coefficient; abuse case; acetate; acetylc...
CCC care-cure coordination; cathodal closure contraction; chronic calculous cholecystitis; chronic catar...
CF calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ...
CFR case-fatality ratio; citrovorum-factor rescue; Code of Federal Regulations; complement-fixation reac...
CH case history; Chediak-Higashi [syndrome]; chiasma; Chinese hamster; chloral hydrate; cholesterol; Ch...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
Study 1 study
Study 2 study
Study A study
Study B study
Study I study
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • study cast
    ¿¬±¸¿ë ¸ðÇü, Áø´Ü ¸ðÇü
    µ¿ÀǾî=diagnostic cast.
  • video-urodynamic study
    ºñµð¿À ¿ä¿ªÇÐ °Ë»ç
  • admission by legal control
    Á¶Ä¡ ÀÔ¿ø
  • birth control
    ÇÇÀÓ¹ý
    ¼öŸ¦ ÀΰøÀûÀ¸·Î Á¶ÀýÇÏ´Â ÀÏ. Àü¿¡´Â »ê¾Æ Á¦ÇÑ, Ãâ»ê Á¶ÀýÀ̶ó°í ÇßÀ¸³ª Á¶Àý ´ë»óÀº ºÐ¸¸ÀÌ ¾Æ´Ï°í ¼öÅÂÀ̱⠶§¹®¿¡ ¼öÅ Á¶Àý·Î °³Á¤µÇ¾ú´Ù. ¸ðüÀÇ °Ç°­À̳ª °æÁ¦ÀûÀÎ ÀÌÀ¯ µîÀ¸·Î ÀÓ½ÅÇØ¼­´Â °ï¶õÇÑ »çÁ¤ÀÌ ÀÖÀ» ¶§ ÇÇÀÓÀ» °è¼ÓÇϰí, ¾ÆÀ̰¡ ÇÊ¿äÇØÁö¸é ÇÇÀÓÀ» ÁßÁöÇϰí ÀÓ½ÅÇÒ ¼ö ÀÖµµ·Ï ÀÎÀ§ÀûÀÎ ¼ö´ÜÀ» »ç¿ëÇØ¼­ ¼öŸ¦ ÀΰøÀûÀ¸·Î Á¶ÀýÇÏ¿© »ê¾Æ¸¦ Á¦ÇÑÇÏ´Â °ÍÀÌ´Ù. ÀÌ¹Ì ÀÓ½ÅÇÑ °ÍÀ» ÀΰøÀûÀ¸·Î ÁßÀýÇÏ´Â °ÍÀº ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾Ê´Â´Ù. Áï, ÇÇÀÓÀÇ ½ÇÆÐ´Â µµ¸®°¡ ¾ø±â ¶§¹®¿¡ ¹Ù¸¥ ÇÇÀÓÀÇ Áö½ÄÀ» ¾ò¾î ÀûÀýÇÑ ÇÇÀÓ¹ýÀ» ¼±ÅÃÇØ¼­ ¹Ù¸£°Ô ½ÃÇàÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù. ¼öÅ Á¶Àý¿¡ ÀÀ¿ëµÇ´Â ÇÇÀÓ¹ýÀº ¼öÁ¤ ÀúÁö¹ý°ú ¼öÅ ÀúÁö¹ýÀ¸·Î ´ëº°µÇÁö¸¸ ¸ðµÎ ÀϽÃÀûÀÎ ÇÇÀÓ¹ýÀÌ´Ù. À̰ÍÀº ±¹°¡°¡ ÁÖüÀÎ °æ¿ì¿¡´Â Àα¸ Á¤Ã¥ÀÌ µÇ¸ç, °¡Á¤ÀÌ ÁÖüÀÎ °æ¿ì¿¡´Â °¡Á· °èȹÀÌ µÇ´Â °¡Àå ÇÕ¸®ÀûÀÎ ¼ö´ÜÀÌ´Ù. ½Ç¿ëÀûÀÎ ¸é¿¡¼­ ºÐ·ùÇÑ ÇÇÀÓ¹ýÀº ´ÙÀ½°ú °°´Ù. ¡¼¹è¶õÀÏ ÀüÈÄÀÇ ¼º±³¸¦ ÇÇÇÏ´Â ¹æ¹ý¡½ ¹è¶õÀÏ ÀüÈÄ ¼öÀϰ£À» ±Ý¿åÇÔÀ¸·Î½á ¼öÁ¤À» ¹Ì¸® ¸·´Â °ÍÀ¸·Î, ¹è¶õÀÏÀ» ¿¹»óÇÏ´Â ¹æ¹ý¿¡´Â 2°¡Áö°¡ ÀÖ´Ù. ¨ç ¿À±â³ë½Ä ¼öÅ Á¶Àý¹ý : Çѱ¹¿¡¼­ °¡Àå ³Î¸® º¸±ÞµÇ¾î ÀÖ´Â ¹æ¹ýÀ¸·Î, ¿ù°æ ÁֱⰡ Á¤È®ÇÏ°Ô µ¹¾Æ¿À´Â ¿©¼º¿¡°Ô¸¸ Àû¿ëÀÌ °¡´ÉÇÏ´Ù. 28ÀÏÇüÀÎ ¿©¼ºÀÇ °æ¿ì ¿ù°æ Á¦1ÀϰºÎÅÍ ¼¼¾î¼­ Á¦14Àϰ°¡ µÇ´Â ³¯ÀÇ Àü 3Àϰ£°ú ÈÄ 2Àϰ£ÀÌ °¡Àå ÀÓ½ÅÇϱ⠽¬¿î ³¯·Î º¸°í ÀÌ ±â°£Àº ¼º±³¸¦ ÇÇÇÑ´Ù. ÀÌ ¹æ¹ýÀº ¿ù°æ ÁֱⰡ ºÒ±ÔÄ¢ÇÑ ¿©¼ºÀÇ °æ¿ì¿¡´Â ½ÇÆÐÀÇ È®·üÀÌ Å©´Ù. ¨è ±âÃÊ Ã¼¿ÂÇ¥¸¦ ÀÀ¿ëÇÏ´Â ¹æ¹ý : ¸ÅÀÏ ±âÃÊ Ã¼¿ÂÀ» ÃøÁ¤Çؼ­ ±âÃÊ Ã¼¿Â °î¼±ÀÌ °í¿Â»óÀÌ µÇ¾î 2ÀÏÀÌ °æ°úÇßÀ» ¶§´Â °ÅÀÇ ÀÓ½ÅÇÏÁö ¾Ê´Â °ÍÀ¸·Î ³ªÅ¸³ª ÀÖ¾î 3ÀÏ ÀÌÈĺÎÅÍ ¼º±³¸¦ °®´Â ¹æ¹ýÀÌÁö¸¸, °í¿Â»óÀÎÁö Àú¿Â»óÀÎÁö¸¦ Á¤ÇϱⰡ ¶§·Î´Â °ï¶õÇÑ ¶§°¡ ÀÖ´Ù. ¡¼³²¼ºÀÌ ÇÇÀÓ µµ±¸³ª ¾àǰÀ» »ç¿ëÇÏ´Â ¹æ¹ý¡½ ³²¼ºÀÌ ¼º±³ ¶§ Äܵ¼À» ½á¼­ ¼öÁ¤À» ÀúÁöÇÏ´Â ¹æ¹ýÀÌ °¡Àå ÀϹÝÀûÀÌ´Ù. Äܵ¼Àº ³²¼º ¼º±â¿¡ ¾º¿ö¼­ »ç¿ëÇÏ´Â ¾ãÀº °í¹« Á¦Ç°ÀÎ Á¡¿¡¼­ ³²¼ºÀÌ »ç¿ë°¨À» °¡Áö°Ô ÇÑ´Ù´Â °áÁ¡ÀÌ ÀÖ°í, ¿©¼º¿¡°Ô´Â ½É¸®ÀûÀÎ ¹®Á¦¸¦ Æ÷ÇÔÇÏ¿© ¿©·¯ °¡Áö °áÁ¡ÀÌ ÁöÀûµÇ°í ÀÖÁö¸¸, ½ÇÆÐÀ²ÀÌ ³·°í ÀϹÝÀûÀ¸·Î ½±°Ô ±¸ÇÒ ¼ö ÀÖÀ¸¸ç ´©±¸³ª »ç¿ëÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÌ ´Ù¸¥ ¹æ¹ý¿¡ ºñÇØ ÀåÁ¡ÀÌ´Ù. ƯÈ÷ ÃÖ±Ù¿¡´Â °í¹«ÀÇ ÁúÀÌ °³·®µÇ°í Á¦Ç°ÀÇ Ç°ÁúÀÌ Çâ»óµÇ¾î ÆÄ¼ÕÀÇ ¿ì·Áµµ ¾ø´Ù. ÀÌ ¹Û¿¡ Á¤ÀÚ¸¦ ¸¸µå´Â ÈûÀ» ¾àÈ­½Ãų ¸ñÀûÀ¸·Î ³²¼º¿¡°Ô ÇÇÀÓ ¾àÀ» ¾²°Ô ÇÏ´Â °æ¿ìµµ ÀÖÀ¸³ª, ÇÇÀÓÀÇ ¸ñÀûÀº ´Þ¼ºÇß´Ù ÇØµµ °¡²û ³²¼ºÀÇ ¼º¿åÀ» ÀúÇϽÃŲ´Ù ÇÏ¿© ½Ç¿ëµÇÁö ¾Ê°í ÀÖ´Ù. ¡¼ÁßÀý ¼º±³¹ý¡½»çÁ¤ Àü¿¡ ¼º±³¸¦ Áß´ÜÇϰí Áú ¿ÜºÎ¿¡ »çÁ¤ÇÏ´Â ¹æ¹ýÀε¥ Áú ¾È¿¡ Á¤¾×À» µé¿©º¸³»Áö ¾Êµµ·Ï ÇØ¼­ ÀÓ½ÅÀ» ÇÇÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ´Ù. ÀÌ ¹æ¹ýÀº Ưº°ÇÑ ±â±¸¸¦ ÇÊ¿ä·Î ÇÏÁö ¾ÊÀ¸¸ç ¾î·Á¿ò ¾øÀÌ ÇÒ ¼ö ÀÖ´Â ÀåÁ¡µµ ÀÖÁö¸¸, ÇÇÀÓÀ̶ó´Â ¸ñÀû ¶§¹®¿¡ ¼º°¨À» Èñ»ýÇÏ°Ô µÇ´Â °æÇâÀÌ °­ÇÏ´Ù. ´õ¿íÀÌ °áÁ¤ÀûÀÎ °áÁ¡Àº ÀÓ½ÅÀÇ À§Çèµµ Å©´Ù´Â Á¡ÀÌ´Ù. ¡¼¿©¼ºÀÌ ±â±¸¸¦ »ç¿ëÇÏ´Â ¹æ¹ý¡½¨ç Æä¼­¸®
  • bite control
    ±³ÇÕ Á¶Á¤
    ±³ÇÕ°£ °ü°è³ª ±× Ç¥½Ã¸¦ Á¶Á¤ÇÏ´Â °Í.
  • control animal
    ´ëÁ¶ µ¿¹°
  • control equipment
    Á¦¾î ÀåÄ¡
  • control gene
    Á¦¾î À¯ÀüÀÚ
  • control of bleeding
    ÁöÇ÷¹ý
  • control panel
    Á¶Á¾ÆÇ
  • control system
    Á¶Àý°è
  • control valve
    Á¶Àý ¹ëºê, Á¶ÀýÆÇ
  • laser hazard control measure
    ·¹ÀÌÀú À§ÇØÁ¶Àý¹ý
    ·¹ÀÌÀú°¡ Áö´Ñ ¾öû³­ ¿¡³ÊÁö´Â ÀÎü¿¡ ÇØ°¡ µÉ ¼ö ÀÖÀ¸¹Ç·Î µÇµµ·Ï ·¹ÀÌÀú¸¦ »ç¿ëÇÏ´Â »ç¶÷µéÀÌ ¼Õ»óÀ» ¹ÞÁö ¾Êµµ·Ï ÇÏ´Â ¹æ¹ý.
  • leprosy control
    ³ª °ü¸®
    °³³ä»ó, ÁÖ¹ÎÀ» ³ª±ÕÀÇ Àü¿°À¸·ÎºÎÅÍ º¸È£ÇÏ´Â ¿¹¹æ °ü¸®¿Í, ³ªÈ¯ÀÚ¸¦ ³ª±ÕÀ¸·ÎºÎÅÍ ¿À´Â À°Ã¼Àû, Á¤½ÅÀû °íÅëÀ» ´ú¾î ÁÖ´Â Áø·á °ü¸®ÀÇ µÎ °¡Áö·Î ºÐ·ùÇÒ ¼ö ÀÖ´Ù. ¨ç ¿¹¹æ °ü¸®´Â Àü¿°¿øÀ» Â÷´ÜÇÏ´Â °ÍÀ» ¸»Çϴµ¥, ³ª ȯÀÚ¸¦ °Ý¸®ÇÔÀ¸·Î½á ³ªº´ÀÇ Àü¿°¿øÀÌ Â÷´ÜµÈ´Ù°í »ý°¢Çß´ø ½Ã´ë¿¡´Â ³ª ȯÀÚ Àü¿øÀ» °Ý¸® ¼ö¿ëÇÏ¿´´Ù. ±×·¯³ª Àüü ³ª ȯÀÚ Áß ±ØÈ÷ ÀϺÎÀÇ ¹Ì°ü¸®ÇÏ¿¡ Àִ ȯÀÚ¸¸ÀÌ Àü¿°¿øÀÌ µÈ´Ù´Â »ç½ÇÀÌ ¹àÇôÁø ¿À´Ã³¯¿¡´Â, ³ª ȯÀÚ·Î È®ÀÎÀÌ µÇ¾î ¾àÁ¦ Åõ¿©°¡ ½ÃÀÛµÈ ÈÄ¿¡´Â Àü¿°¿øÀÌ µÉ ¼ö ¾ø´Ù´Â °á·Ð¿¡ À̸£·¶´Ù. ÀÌ¿¡ µû¶ó ¿À´Ã³¯¿¡´Â ÀÏ¹Ý ÇǺΠÁúȯÀÚ¿Í °°ÀÌ ÀÚÀ¯·ÎÀÌ »ý¾÷¿¡ Á¾»çÇϸç Áø·á¸¦ ¹Þ°í ÀÖ´Ù. ¨è Áø·á °ü¸®´Â Àǻ簡 Á¤È®ÇÑ Áø´Ü°ú º´Çü ºÐ·ù¸¦ ¹ÙÅÁÀ¸·Î ÀûÇÕÇÑ Ã³¹æÀ» ³»¸®°í ȯÀÚ°¡ ¼º½ÇÇÏ°Ô ¾àÀ» º¹¿ëÇÏ´Â °ÍÀÌ´Ù. ¹®Á¦´Â ³ªº´ÀÌ ¸¸¼ºÀûÀ¸·Î °æ°úÇÏ´Â Àå±â ÁúȯÀε¥´Ù Ä¡·áÀÇ ¼º°ú°¡ Áï½Ã ³ªÅ¸³ªÁö ¾ÊÀ¸¹Ç·Î 󹿰ú º¹¾àÀÌ ³ªÅÂÇØÁ® Ä¡·á°¡ ºÒ±ÔÄ¢ÇØÁö°í ¾àÁ¦ ³»¼ºÀ» ¹ßÀü½ÃŰ´Â µ¥ µû¸¥ °ü¸®»óÀÇ ¾î·Á¿òÀÌ ÀÖ´Ù. ³ªº´¿¡ ´ëÇÑ Æí°ßÀ» ¾ø¾Ö°í ±¹¹ÎÀû ÀÌÇØ¿Í Âü¿©¿¡ ÀÇÇØ Á¶±â ¹ß°ß ¹× Ä¡·á¿¡ ÀÓÇÑ´Ù¸é ³ªº´ °ü¸®¸¦ À§ÇÑ Æ¯¼ö ½Ã¼³À̳ª ±â°üÀÌ ÇÊ¿ä¾ø°Ô µÉ °ÍÀÌ´Ù.
  • nociceptive control
    Ä§ÇØ ¼ö¿ë¼º Á¶Àý, À¯ÇØ ¼ö¿ë¼º Á¶Àý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
diachronic study A study done over the course of time. For example, a longitudinal study of children with Down syndrome (trisomy 21) might involve the study of 100 children with this condition from birth to 10 years of age. Also called a longitudinal study. The opposite of a synchronic (cross-sectional) study.
(12 Dec 1998)
double-blind study A study in which neither the experimenter nor any other assessor of the results, including patients, know which group is subject to which procedure, thus helping assure that the biases or expectations of either will not influence the results.
(05 Mar 2000)
epidemiologic study characteristics Types and formulations of studies used in epidemiological and clinical research.
(12 Dec 1998)
twin study A method of detecting genetic causes in human traits and genetic factors in behaviour using sets of twins.
(12 Dec 1998)
foetal doppler study <radiology> Non-stress test (NST), external monitoring for 20 minutes; poor specificity, greater than4 foetal heart accelerations (greater than15 bpm over baseline for 15 seconds) following foetal movement in foetus greater than34 weeks, no heart accelerations in immaturity, sleep, maternal sedation contraction stress test (CST), external monitoring after oxytocin or maternal breast stimulation, greater than 3 uterine contraction in 10 minutes; 50% specificity uterine and umbilical artery waveform, elevated systolic:diastolic ratio = increased vascular resistance foetal aortic flow volume, 185-246 ml/kg/min see also: biophysical profile, intrauterine growth retardation (IUGR)
(12 Dec 1998)
follow-up study Study in which persons exposed to risk or given a designated preventive or therapeutic regimen are observed over a period or at intervals to determine the outcome of the exposure or regimen.
(05 Mar 2000)
Framingham Heart study <epidemiology> Ongoing epidemiologic study of a cohort of over 5,000 of the population of Framingham, MA conducted since 1949 under the auspices of the National Institutes of Health and Boston University.
(05 Mar 2000)
longitudinal study <epidemiology> A study taking place over time. If individuals are followed, this is a longitudinal cohort study. If individuals are not followed, but classes (usually age classes) are restudied, this is a longitudinal cross-sectional study.
The converse of a horizontal study.
(05 Dec 1998)
acceptor control <biochemistry> The regulation of the respiration rate, governed by ADP's ability to be a phosphate group acceptor.
(06 May 1997)
anticipatory control <physiology> The regulation of a system or process based on anticipated events, this isa feed-forward rather than a feedback system.
(09 Oct 1997)
assist-control ventilation Artificial respiration in which inspiration is produced automatically after a set interval if the person has not already begun to inspire.
Compare: assisted ventilation, controlled ventilation.
(05 Mar 2000)
autogenous control <molecular biology> Regulation of how much a gene gets transcribed by the gene's own products.
(02 Jan 1998)
aversive control <psychology> Control of the behaviour of another individual by use of psychologically noxious means; e.g., attempting to force better study habits by withholding a child's allowance, or withholding sexual contact unless the partner complies with a request.
(05 Mar 2000)
biological control <agriculture> The agricultural use of living things, such as parasites, diseases, and predators, to control or eliminate others, such as weeds and pests, rather than by using chemicals (herbicides and pesticides).
(21 Mar 1998)
birth control Restriction of the number of offspring by means of contraceptive measures, projects, programs, or methods to control reproduction, by either improving or diminishing fertility.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cold case
    ¸Å¿ì ³ª»Û »óȲ;±ÃÁö
  • cot case
    °ÉÀ» ¼ö ¾ø´Â (´©¿ö ÀÖ´Â)ȯÀÚ;°ïµå·¹ ¸¸µå·¹ ÃëÇÑ »ç¶÷
  • couch case
    Á¤½Å Àå¾ÖÀÚ
  • dressing case
    ¿©ÇØ¿ë È­Àåǰ ±×¸©
  • emergency case
    ±¸±Þ »êÀÚ
  • fiddle case
    ¹ÙÀ̿ø° ÄÉÀ̽º
  • glass case
    À¯¸®¸¦ ³ÖÀº »óÀÚ;À¯¸® ±×¸©(Áø¿­Àå)
  • hard case
    ³­Ä¡º´ ȯÀÚ,ȸº¹ ºÒ°¡´ÉÇÑ È¯ÀÚ,°³ÀüÀÇ Á¤ÀÌ ¾ø´Â ÁËÀÎ,»ó½À¹ü(ÀÚ);ºÒ·®¹è;ó¸®Çϱ⠾î·Á¿î »ç°Ç
  • hunting case
    hunter 4ÀÇ °Ñ ¶Ñ²±
  • leading case
    ¼±·Ê°¡ µÇ´Â ÆÇ°á·Ê
  • lower case
    ¼Ò¹®ÀÚ¿ë ÄÉÀ̽º
  • mental case
    Á¤½Åº´ ȯÀÚ
  • needle case
    ¹Ù´Ã½Ó
  • objective case
    ¸ñÀû°Ý
  • oblique case
    »ç°Ý(ÁÖ°Ý,È£°Ý ÀÌ¿ÜÀÇ °Ý)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á